Developing innovative biologics
JJP Biologics is a Polish biotechnology company developing novel biologics for the treatment of a range of disease indications. We have multiple (pre)clinical programs that we plan to develop until clinical proof of concept.
All our programs focus around early selection of companion diagnostics, enabling stratification of patients for a personalized medicine strategy. We choose to focus on programs where companion diagnostics are available because this enables selection of relevant patients which increases chances that the therapeutic will be effective and reduces unwanted side-effects and development costs.
Our innovative molecules target general immune pathways with application across various indications and disease areas. Our current pipeline includes our lead-program JJP-1212, a potential first-in-class CD89 antagonist for autoinflammatory diseases and JJP-1008, a potential first-in-class HVEM checkpoint inhibitor for the treatment of solid tumours.
Collaborate with us
We are always looking for the next innovation or advancement in the biotechnology field, especially when companion diagnostics are available. If you are working in academia or biotechnology on a new target, we would be interested in working with you. We are also always looking for potential partners and investors interested in our existing pipeline to help us commercialize and reach patients.
Our Leadership
Our leadership team is hugely experienced in bringing new biologics to the market. Between them they have brought many new biologics through development, including bringing the first biosimilars to the European market, doing pioneering research into a variety of conditions and founding several companies.
Our Investors
JJP Biologics is ultimately owned by the Starak family which provides stable financial and business foundations for the activities of our company.
Jerzy Starak is one of the most successful Polish entrepreneurs, whose activities contributed to the development and modernization of the Polish economy. A visionary, who does not lack the courage, determination and perseverance in constantly undertaking new business challenges and turning them into successful business operations. Committed investor, patron of art, philanthropist supporting young talents and people of science.
For the last more than 20 years, Mr. Jerzy Starak’s business activity has been primarily oriented towards the pharmaceutical sector, initially generics and subsequently biosimilars.
In 2000, he privatized Polpharma and transformed it from a local pharmaceutical business into a national champion, a leader of the Polish pharmaceutical market, and one of the largest pharmaceutical groups in Central and Eastern Europe delivering advanced generics and APIs to patients and business partners worldwide.
In the wake of successes in the area of generic drugs, Jerzy Starak invested in the creation and the development – practically from scratch – of biotechnology, a new sector in Polish economy at the time. His efforts led to the establishment of Polpharma Biologics, Poland’s largest biotechnology group, which develops and will manufacture biosimilar drugs on a global scale in the facilities which can be counted among the most advanced of its kind in Europe.
Focus on innovation and development of novel biologics in Poland is the next investment step taken by Mr. Jerzy Starak and his family to be implemented through JJP Biologics. With his long track record in building successful companies based on advanced competences JJP Biologics has a great potential and ambition to develop close collaboration with Polish scientists and business partners worldwide with the aim of developing and making innovative antibody molecules widely available for the therapy of patients.